Hao et al. meta-analyzed six RCTs (3,284 advanced melanoma patients) and found that anti-PD-1 monotherapy and nivolumab/ipilimumab combination significantly improved OS and PFS versus chemotherapy or ipilimumab alone. Here, PDCD1 is linked to melanoma.